Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03458546 (Phase Ib Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy for High-risk Diffuse Large B-cell Lymphoma), which is not on this map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase Ib Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy for High-risk Diffuse Large B-cell Lymphoma
TypeinterventionalSponsorThe University of Texas Health Science Center at San AntonioRan2018 to 2024Enrolled14ConditionsLymphoma, B-CellArmsRoflumilast
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Adolfo E Diaz DuqueDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.ORCID 0009-0004-9941-7697
Pedro S S M FerrariDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
Purushoth EthirajDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-0679-6041
Carine JaafarDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-3107-573X
Zhijun QiuDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
Kenneth HolderDepartment of Pathology, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
Mathew J ButlerDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-8072-2614
Gabriela Huelgas-MoralesDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
Anand KarnadDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
Patricia L M DahiaDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
Ricardo C T AguiarDivision of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-8791-5849
Funding
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Evaluating the impact of genetic ancestry on the biology and drug response profile of pheochromocytoma and paraganglioma-derived organoid modelsR01CA264248 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAHIA, PATRICIA LEAL, SORAGNI, ALICE · 2021 to 2025
$3.2M
Oxidative stress and RNA methylationR01ES031522 · NIEHS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI AGUIAR, RICARDO C · 2020 to 2024
$1.9M
Interaction of the TMEM127 tumor suppressor with the mTORC1 lysosomal activating complexR01GM114102 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAHIA, PATRICIA LEAL · 2017 to 2021
$1.5M
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptomeR01GM140456 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI AGUIAR, RICARDO C · 2021 to 2024
$1.2M
BLRD VA I01 BX001882BLRD VA IK6 BX006542Cancer Prevention and Research Institute of Texas RP170146Leukemia and Lymphoma Society TRP-6524-17NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA264248NIEHS NIH HHS R01 ES031522NIGMS NIH HHS R01 GM114102NIGMS NIH HHS R01 GM140456
6 · The paper itself
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is a common and often fatal malignancy. The standard-of-care immunochemotherapy, R-CHOP, cures only about 60% of DLBCL patients. Improving this cure rate will likely require the effective translation of basic biology knowledge into clinical activities. We previously identified the cyclic-AMP/phosphodiesterase 4 (PDE4) axis as an important modulator of lymphomagenic processes. We also showed that the FDA-approved PDE4 inhibitor roflumilast can suppress B-cell receptor (BCR) signals, phosphoinositide 3-kinase (PI3K) activity and angiogenesis. These data suggested that combining roflumilast with R-CHOP may be beneficial in DLBCL.
methodsWe conducted a single-center, single-arm, open-label, phase 1 study of roflumilast in combination with the standard of care, R-CHOP (Ro+R-CHOP), in pathologically proven, treatment-naïve, high-risk DLBCL patients.
resultsRo+R-CHOP was safe, and at a median follow-up time of 44 months, 70% of patients were alive and disease free (median OS not reached, PFS 44% (95% CI, 21-92). In this pilot series, we found that the addition of roflumilast suppressed PI3K activity in peripheral blood mononuclear cells, and VEGF-A secretion in the urine. We also encountered preliminary evidence to suggest that the Ro+R-CHOP combination may be particularly beneficial to patients diagnosed with high-risk genetic subtypes of DLBCL, namely MCD and A53.
conclusionsThese initial findings suggest that roflumilast may be an alternative agent able to inhibit BCR/PI3K activity and angiogenesis in DLBCL, and that the testing of Ro+R-CHOP in a larger series of genetically characterized tumors is warranted. This study was registered at ClinicalTrials.gov, number NCT03458546.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL. · full record | Socratic